Jefferies Believes Sangamo Biosciences (NASDAQ: SGMO) Won’t Stop Here

By Jason Carr

Jefferies analyst Eun Yang reiterated a Buy rating on Sangamo Biosciences (NASDAQ: SGMO) on September 12 and set a price target of $18. The company’s shares opened today at $13.25, close to its 52-week high of $15.05.

According to, Yang is a 4-star analyst with an average return of 5.8% and a 52.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, DBV Technologies SA – American, and Iovance Biotherapeutics Inc.

Sangamo Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $13.

The company has a one year high of $15.05 and a one year low of $2.65. Currently, Sangamo Biosciences has an average volume of 1.53M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Lanphier O. Edward II on June 22, 1995 and is headquartered in Richmond, CA.